Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.50 |
| ▸ | DRD4 | P21917 | 4/20 | 0.50 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10816114 | 0.93 | OPRK1 (0.49) | DRD2DRD4DRD3ALDH1A1POLB | |
| SCHEMBL9412858 | 0.85 | DRD2 (0.41) | DRD2DRD4DRD3ALDH1A1POLB | |
| SCHEMBL1427493 | 0.83 | OPRM1 (0.39) | ALDH1A1 | |
| SCHEMBL17562365 | 0.83 | KMT2A (0.55) | ALDH1A1OPRK1 | |
| SCHEMBL19364501 | 0.82 | CHRM2 (0.53) | ALDH1A1OPRK1 | |
| SCHEMBL29691892 | 0.82 | CHRM2 (0.53) | ALDH1A1OPRK1 | |
| SCHEMBL707808 | 0.82 | CHRM2 (0.53) | ALDH1A1OPRK1 | |
| SCHEMBL16766368 | 0.82 | CHRM2 (0.53) | ALDH1A1OPRK1 | |
| SCHEMBL719296 | 0.82 | CHRM2 (0.53) | ALDH1A1OPRK1 | |
| SCHEMBL4145169 | 0.82 | LTA4H (0.46) | DRD2ALDH1A1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240052099-A1 | POLYANHYDRIDES AND METHODS OF MAKING SAME | POLYGENE LTD. (IL) | 2024-02-15 | — | — | US | disclosed |
| EP-4192905-A1 | POLYANHYDRIDES AND METHODS OF MAKING SAME | Polygene Ltd. (IL) | 2023-06-14 | — | — | EP | disclosed |
| EP-1566372-B1 | METHOD OF HYDROGENATION REACTION | NEW JAPAN CHEM CO LTD (JP) | 2018-01-10 | — | — | EP | disclosed |
| EP-1566372-A1 | METHOD OF HYDROGENATION REACTION | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 2005-08-24 | — | — | EP | disclosed |
| EP-1525201-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR1 CHEMOKINE RECEPTOR | Pfizer Products Inc. (US) | 2005-04-27 | — | — | EP | disclosed |
| US-20040063688-A1 | Novel piperidine derivatives | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2004009588-A1 | BICYCLIC PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR1 CHEMOKINE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| EP-0152003-A1 | Process for the preparation of alpha-hydroxyaryl-alkanoic acids | ZAMBON S.p.A. (IT) | 1985-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240052099-A1 | POLYANHYDRIDES AND METHODS OF MAKING SAME | PUF60, DDOST, PARG | DRD2 2965/4885DRD4 1238/4885DRD3 2787/4885 |
| US-20040063688-A1 | Novel piperidine derivatives | CCR1, CCR3, CCR2 | DRD2 475/4885DRD4 634/4885DRD3 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.